Online citations, reference lists, and bibliographies.

Vascular Endothelial Growth Factor: Basic Biology And Clinical Applications

N. Ferrara
Published 2009 · Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Vascular endothelial growth factor (VEGF)-A is a well-characterized angiogenic factor involved in physiological and pathological growth of blood vessels. The homologous tyrosine kinases VEGFR-1 and VEGFR-2 are the main VEGF-A receptors. Much evidence indicates that VEGF-A is important in tumor angiogenesis. Humanized anti-VEGF-A monoclonal antibodies and two small-molecule inhibitors of VEGF receptor signaling have been approved by the US Food and Drug Administration (FDA) for cancer therapy. Furthermore, VEGF-A is implicated in intraocular neovascularization associated with active proliferative retinopathies and the neovascular form of age-related macular degeneration (AMD).
This paper references
10.1172/JCI18181
HIF hydroxylation and the mammalian oxygen-sensing pathway.
M. Safran (2003)
10.1097/00000658-198012000-00012
Angiogenic Activity as a Marker of Neoplastic and Preneoplastic Lesions of the Human Bladder
G. Chodak (1980)
Identification of a new endothelial cell growth factor receptor tyrosine kinase.
B. Terman (1991)
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
J. Rak (1995)
10.1073/pnas.90.16.7533
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.
T. Quinn (1993)
10.1200/JCO.2005.01.5388
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
A. Jubb (2006)
Human vascular permeability factor. Isolation from U937 cells.
D. Connolly (1989)
10.1161/01.CIR.91.11.2793
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery.
T. Asahara (1995)
10.1016/0922-3371(90)90046-Y
Proteolytic balance and capillary morphogenesis.
M. Pepper (1990)
10.1016/j.bbrc.2012.08.021
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. 1989.
N. Ferrara (1989)
10.1172/JCI5028
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.
L. Benjamin (1999)
10.1001/archopht.1996.01100140172010
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.
M. Tolentino (1996)
10.1056/NEJMOA061884
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
10.1002/path.1711390314
The potential aggressiveness of synovial tissue in rheumatoid arthritis
H. Fassbender (1983)
10.1097/00000441-194708000-00035
Peripheral Vascular Diseases
E. Allen (1947)
10.1016/0002-9378(81)90438-5
The significance of atypical vessels and neovascularization in cervical neoplasia.
F. Sillman (1981)
10.1152/ajpheart.1992.262.6.H1669
Endothelial modulation of porcine coronary microcirculation perfused via immature collaterals.
F. Sellke (1992)
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.
L. Pertovaara (1994)
10.1074/jbc.270.17.9709
Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*)
S. Mandriota (1995)
10.1126/science.1312256
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
C. de Vries (1992)
Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor
D. Maglione (1991)
10.1083/jcb.129.4.895
Endothelial receptor tyrosine kinases involved in angiogenesis
T. Mustonen (1995)
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
J. Park (1994)
10.1152/ajpcell.1993.264.4.C995
Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues.
W. T. Monacci (1993)
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.
J. Pe’er (1995)
10.1083/jcb.108.2.671
In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases
P. Mignatti (1989)
10.1097/00006982-199515020-00021
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.
J. W. Miller (1994)
10.1016/1050-1738(93)90046-9
Vascular endothelial growth factor.
N. Ferrara (1993)
The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases
I. Michaelson (1948)
10.1007/BF03401566
Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen
D. Shima (1995)
10.1006/bbrc.1996.1556
Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia.
S. Takeshita (1996)
Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors.
C. Rosenberg (1993)
Studies on retinal neovascularization. Friedenwald Lecture.
A. Patz (1980)
10.1074/jbc.271.13.7788
The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*)
B. Keyt (1996)
10.3727/000000003772462298
Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.
J. Smith (2004)
10.1016/S0002-9440(10)64773-6
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
H. Ozaki (2000)
10.1038/ncponc0342
Angiogenic inhibitors: a new therapeutic strategy in oncology
G. Gasparini (2005)
10.1016/0046-8177(95)90119-1
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.
L. F. Brown (1995)
10.1073/pnas.88.20.9026
A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.
W. Matthews (1991)
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.
K. Houck (1992)
10.1158/1078-0432.CCR-05-1770
Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma
M. Tejada (2006)
10.1074/jbc.271.10.5638
Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors
B. Keyt (1996)
10.1038/376066a0
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
G. Fong (1995)
10.1152/ajpheart.1993.265.2.H586
Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries.
David D. Ku (1993)
10.1093/cvr/28.8.1176
Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis.
S. Banai (1994)
10.1016/0006-291X(92)92277-5
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.
M. Pepper (1992)
10.1007/978-1-4612-0213-4_16
Placenta Growth Factor
M. Persico (2001)
10.1038/nature04480
Lymphangiogenesis in development and human disease
K. Alitalo (2005)
10.1073/pnas.88.20.9267
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
D. Maglione (1991)
10.1038/nrm1911
VEGF receptor signalling ? in control of vascular function
A. Olsson (2006)
10.1200/JCO.2006.09.6305
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
B. Giantonio (2007)
10.1084/jem.172.6.1535
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
M. Clauss (1990)
10.3109/08977199209023937
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.
K. Kim (1992)
10.3109/08977199309046931
Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells.
C. Garrido (1993)
10.1016/J.CCR.2005.09.005
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
O. Casanovas (2005)
10.1056/NEJMOA065044
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
10.1210/endo.133.2.7688292
Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis.
L. Jakeman (1993)
10.1136/hrt.49.4.393
Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration.
C. E. Essed (1983)
Hypothesis: in vitro evidence for the invasive and tumor-like properties of the rheumatoid pannus
Hamilton Ja (1983)
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.
D. Senger (1986)
10.1111/1523-1747.ep12606974
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme.
L. F. Brown (1995)
10.1023/A:1013172910858
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
R. Kerbel (2004)
10.1038/nm1095-1024
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
T. Alon (1995)
10.1038/nature04478
Angiogenesis in life, disease and medicine
P. Carmeliet (2005)
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.
L. F. Brown (1993)
Vascular permeability factor gene expression in normal and neoplastic human ovaries.
T. Olson (1994)
10.1073/pnas.54.4.1197
Specific degradation of the collagen molecule by tadpole collagenolytic enzyme.
J. Gross (1965)
10.1016/S1535-6108(02)00153-8
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.
S. Hiratsuka (2002)
10.1038/362841a0
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
K. J. Kim (1993)
10.1038/nm0603-669
The biology of VEGF and its receptors
N. Ferrara (2003)
10.1172/JCI116450
Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.
D. Shweiki (1993)
10.1056/NEJMOA062655
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
D. Brown (2006)
10.1038/nature04483
Angiogenesis as a therapeutic target
N. Ferrara (2005)
Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea.
G. D. Phillips (1994)
10.3109/08977199009011010
Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor.
R. Rosenthal (1990)
Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.
M. Goldberg (1994)
10.1126/science.6823562
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
D. Senger (1983)
10.1056/NEJM199101033240101
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
N. Weidner (1991)
10.1172/JCI116165
Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.
R. Berkman (1993)
10.1073/pnas.072586399
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Jennifer Tran (2002)
10.1038/nrd1381
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N. Ferrara (2004)
Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma.
R. Vartanian (1994)
A Dynamic Approach
R. Dunn (1989)
10.1016/0006-291X(91)91276-I
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells.
M. Pepper (1991)
10.1200/JCO.2005.23.16_SUPPL.9011
Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)
R. Maki (2005)
10.1126/SCIENCE.1079562
Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1
J. Lecouter (2003)
10.1073/PNAS.95.20.11709
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.
B. Olofsson (1998)
10.1073/PNAS.0500180102
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors.
M. Sund (2005)
10.1056/NEJMOA042760
Pegaptanib for neovascular age-related macular degeneration.
E. Gragoudas (2004)
10.1172/JCI116877
Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.
R. Meyer-Schwickerath (1993)
10.1083/jcb.200409115
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors
Sunyoung Lee (2005)
Clinical ischemic syndromes : mechanisms and consequences of tissue injury
G. Zelenock (1990)
10.1073/pnas.90.9.3928
A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer.
A. Madan (1993)
10.1146/annurev.ph.53.030191.001245
Regulators of angiogenesis.
M. Klagsbrun (1991)
10.1038/nbt1323
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
F. Shojaei (2007)
10.1016/0140-6736(92)93150-L
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
E. Horak (1992)
10.1016/0140-6736(92)93217-B
Relation of neovascularisation to metastasis of non-small-cell lung cancer
P. Macchiarini (1992)
Textbook of Interventional Cardiology
E. Topol (1999)
10.1038/359845a0
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
K. Plate (1992)
10.1210/endo-127-2-965
Vascular endothelial growth factor is expressed in rat corpus luteum.
H. Phillips (1990)
10.1038/nrd1955
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Eugene W. M. Ng (2006)
10.1084/jem.180.1.341
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue
R. Fava (1994)
10.1097/01.iae.0000242842.14624.e7
DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
N. Ferrara (2006)
10.1097/00001573-199010000-00017
Interventional treatment of peripheral vascular disease
R. Graor (1990)
10.1016/S0140-6736(03)13643-4
von Hippel-Lindau disease
R. Lonser (2003)
10.1038/35025215
Vascular-specific growth factors and blood vessel formation
G. Yancopoulos (2000)
VEGF is required for growth and survival in neonatal mice.
H. Gerber (1999)
Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways.
K. Claffey (1992)
10.1091/mbc.4.12.1317
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.
J. Park (1993)
10.1097/00005344-199601000-00015
Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia.
C. Walder (1996)
10.1001/archopht.1996.01100130062010
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.
A. P. Adamis (1996)
10.1172/JCI114322
Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.
D. Connolly (1989)
10.1210/ER.2003-0027
Vascular endothelial growth factor: basic science and clinical progress.
N. Ferrara (2004)
10.1002/jcp.1041530317
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
E. Unemori (1992)
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.
E. Tischer (1991)
10.1097/00132578-200001000-00022
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
N. Bressler (2001)
10.1210/mend-5-12-1806
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.
K. Houck (1991)
10.1073/pnas.92.12.5510
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
G. Wang (1995)
10.1056/NEJM199412013312203
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
L. Aiello (1994)
10.1073/pnas.92.23.10457
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
L. Aiello (1995)
10.1210/endo.131.1.1612003
Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary.
N. Ravindranath (1992)
Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.
G. Breier (1992)
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
L. F. Brown (1993)
10.1126/SCIENCE.1104819
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
R. Jain (2005)
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.
M. Shibuya (1990)
10.1172/JCI115568
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues.
L. Jakeman (1992)
10.1001/archopht.1983.01040010144037
Pathobiology of Ocular Disease
F. Blodi (1983)
10.1074/jbc.270.13.7717
Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor · Placenta Growth Factor Heterodimer (*)
J. Disalvo (1995)
10.1200/JCO.2002.10.088
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
H. Dvorak (2002)
10.1074/jbc.270.22.13333
Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*)
A. Levy (1995)
10.1038/359843a0
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
D. Shweiki (1992)
10.1038/375577a0
Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
D. Mukhopadhyay (1995)
10.1210/edrv-13-1-18
Molecular and biological properties of the vascular endothelial growth factor family of proteins.
N. Ferrara (1992)
10.1074/jbc.273.46.30336
Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway
H. Gerber (1998)
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
A. Koch (1994)
10.1200/JCO.2004.11.022
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
D. Johnson (2004)
The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study.
A. Srivastava (1988)
10.1128/jvi.68.1.84-92.1994
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus.
D. J. Lyttle (1994)
10.1016/0092-8674(93)90573-9
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
B. Millauer (1993)
10.1210/jcem.79.1.8027247
In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action.
J. Shifren (1994)
Vascular endothelial growth factor. The trigger for neovascularization in the eye.
N. Ferrara (1995)
Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin.
P. Pekala (1990)
10.1016/S0092-8674(00)81402-6
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
S. Soker (1998)
A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.
L. Seetharam (1995)
10.1074/jbc.270.3.1230
Purification and Characterization of Hypoxia-inducible Factor 1 (*)
G. Wang (1995)
10.1016/0046-8177(93)90304-Y
Comparison of microscopic vascularity in benign and malignant prostate tissue.
S. Bigler (1993)
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
H. Gerber (2000)
10.1038/367576a0
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
B. Millauer (1994)
10.1172/JCI117857
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
R. Warren (1995)
10.1126/science.2479986
Vascular endothelial growth factor is a secreted angiogenic mitogen.
D. W. Leung (1989)
10.1074/jbc.270.1.308
Induction of Vascular Endothelial Growth Factor Gene Expression by Interleukin-1 in Rat Aortic Smooth Muscle Cells (*)
J. Li (1995)
10.1006/JMBI.1999.3192
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Y. Chen (1999)
10.1200/JCO.2005.23.16_SUPPL.4509
AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)
B. Rini (2005)
10.1074/jbc.270.21.12607
Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes.
S. Frank (1995)
10.1517/13543784.11.12.1715
Therapies directed at vascular endothelial growth factor
P. Manley (2002)
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
C. Lee (2000)
10.1182/blood.V87.8.3336.bloodjournal8783336
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.
B. Barleon (1996)
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
M. Prewett (1999)
10.1126/science.2479987
Vascular permeability factor, an endothelial cell mitogen related to PDGF.
P. J. Keck (1989)
Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential.
T. Sreenath (1992)
10.1016/0006-291X(92)90483-2
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.
B. Terman (1992)
Diabetic retinopathy : practical management
R. Olk (1993)
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
L. Presta (1997)
10.1038/380439a0
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
N. Ferrara (1996)
10.1097/00005344-199606000-00011
Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.
R. Yang (1996)
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
A. Kieser (1994)
10.3109/08977199308991586
A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta.
S. Hauser (1993)
10.1093/jnci/82.1.4
What is the evidence that tumors are angiogenesis dependent?
J. Folkman (1990)
10.1161/01.CIR.89.5.2183
Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs.
S. Banai (1994)
10.1056/nejm198209093071113
[Transluminal coronary angioplasty].
P. Iturralde (1986)
10.1056/NEJMOA054481
Ranibizumab for neovascular age-related macular degeneration.
P. Rosenfeld (2006)
10.1182/BLOOD-2005-05-2047
Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.
A. K. Malik (2006)
10.1073/PNAS.95.7.3609
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.
F. Okada (1998)
10.1093/jnci/84.24.1875
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.
N. Weidner (1992)
10.1002/path.1711680303
Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study.
S. Wakui (1992)
10.1073/pnas.90.19.8915
Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.
K. Peters (1993)
10.1038/ncponc0403
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
R. K. Jain (2006)
Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia.
S. Takeshita (1994)
10.1016/0922-3371(90)90045-X
Growth factor control of extracellular proteolysis.
D. Rifkin (1990)
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
H. Dvorak (1995)
10.1038/NM0398-336
Vascular endothelial growth factor is essential for corpus luteum angiogenesis
N. Ferrara (1998)
10.1073/pnas.172398299
VEGF-Trap: A VEGF blocker with potent antitumor effects
J. Holash (2002)
10.1074/jbc.273.21.13313
Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells*
H. Gerber (1998)
10.1056/NEJMOA060655
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
10.1001/ARCHOPHT.122.4.477
Causes and prevalence of visual impairment among adults in the United States.
N. Congdon (2004)
10.1016/S0002-9394(14)75794-0
Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy
A. P. Adamis (1994)
Demonstration and characterization of the angiogenic properties of cervical dysplasia.
K. Smith-McCune (1994)
Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro.
R. Nicosia (1994)
Characterization of the receptors for vascular endothelial growth factor.
N. Vaisman (1990)
10.1001/archopht.1991.01080070117048
Altered distribution of basic fibroblast growth factor in diabetic retinopathy.
A. Hanneken (1991)
10.1161/01.CIR.91.11.2802
Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor.
C. Bauters (1995)
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
J. Waltenberger (1994)
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.
S. Wizigmann-Voos (1995)
10.1038/sj.emboj.7600289
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Jianying Dong (2004)
10.1002/j.1460-2075.1989.tb08557.x
Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells.
J. Plouët (1989)
10.1146/ANNUREV.MED.58.061705.145635
Targeting VEGF-A to treat cancer and age-related macular degeneration.
N. Ferrara (2007)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1038/376062a0
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
F. Shalaby (1995)
10.1038/nrc909
VEGF and the quest for tumour angiogenesis factors
N. Ferrara (2002)
10.1172/JCI117018
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.
S. Takeshita (1994)
10.1001/archopht.1994.01090230090028
Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy.
F. Malecaze (1994)
10.1111/j.1349-7006.1994.tb02904.x
Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer
M. Toi (1994)
Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing.
H. Dvorak (1987)
10.1001/archopht.1984.01040031330019
Age-related macular degeneration and blindness due to neovascular maculopathy.
F. Ferris (1984)
10.1073/pnas.87.7.2628
Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor.
G. Conn (1990)
10.1172/JCI8829
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G. Klement (2000)
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.
H. Gerber (2005)
10.1038/nm740
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
K. Hattori (2002)
10.1038/9467
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
H. Gerber (1999)
10.1002/j.1460-2075.1992.tb05485.x
Crystal structure of human platelet‐derived growth factor BB.
C. Oefner (1992)



This paper is referenced by
VEGF-induced corneal neovascularisation in a rabbit experimental model
Carol Davila (2010)
10.1016/j.jconrel.2012.07.013
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
S. Taurin (2012)
Proces neoangiogenezy w raku jelita grubego The process of neoangiogenesis in colorectal carcinoma
Marek Kucharzewski (2008)
10.1007/s12282-007-0003-2
Development of new targeted therapies for breast cancer
D. Doyle (2008)
10.3892/OL.2015.3847
Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas.
Manuela Martano (2016)
10.1016/j.lungcan.2008.06.020
Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Ri Cui (2009)
10.1038/sj.bjc.6604929
Why are tumour blood vessels abnormal and why is it important to know?
J. Nagy (2009)
10.1007/s40264-015-0273-0
Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration
Yasha S. Modi (2015)
10.1042/BST20110671
An unexpected tail of VEGF and PlGF in pre-eclampsia.
D. Bates (2011)
10.1016/j.mehy.2016.09.003
Do Demodex mites play a role in pterygium development?
Witold Tarkowski (2017)
10.1016/j.ajpath.2017.06.010
Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
Basel Sitohy (2017)
10.1016/B978-0-12-801344-1.00001-2
Angiogenesis in Peripheral Artery Disease: Focus on Growth Factor Therapy
Aditya Sharma (2016)
10.1155/2018/3180487
Long-Term Effects of Environmental Lead Exposure on Blood Pressure and Plasma Soluble Cell Adhesion Molecules in Young Adults: A Follow-Up Study of a Prospective Cohort in Kosovo
Pashko R. Camaj (2018)
10.1055/s-0039-1687908
Tumors: Wounds That Do Not Heal-A Historical Perspective with a Focus on the Fundamental Roles of Increased Vascular Permeability and Clotting.
Harold F. Dvorak (2019)
10.1158/2326-6066.CIR-14-0209
Tumors: Wounds That Do Not Heal—Redux
H. Dvorak (2015)
10.1371/journal.pone.0021874
The Tissue Microlocalisation and Cellular Expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 Is Correlated to Clinical Outcome in NSCLC
C. Ohri (2011)
10.1111/j.1442-2050.2007.00655.x
Tumor-associated macrophages and CD3-ζ expression of tumor-infiltrating lymphocytes in human esophageal squamous-cell carcinoma.
S-J Guo (2007)
10.1016/S0030-6657(12)70754-0
Molecular pathogenesis of vestibular schwannomas: insights for the development of novel medical therapies.
Craig Miller (2012)
10.1167/IOVS.12-9727
The C allele of -634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue.
F. B. Vailati (2012)
10.5772/59480
Current Insights Into Canine Cutaneous Melanocytic Tumours Diagnosis
Luis Miguel Lima Resende (2015)
10.1016/j.critrevonc.2009.06.001
Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives.
M. Lamuraglia (2010)
10.1152/physiolgenomics.00070.2013
Vascular endothelial growth factor-A signaling in bone marrow-derived endothelial progenitor cells exposed to hypoxic stress.
B. Hoffmann (2013)
10.1007/s40136-014-0063-8
Vestibular Schwannoma Drug Development: Current State-of-the Art
C. Miller (2014)
10.17265/2328-2150/2016.12.006
Short-Term Intra Ocular Pressure Using Intravitreal Bevacizumab
Yolanda Chavéz-Romero (2016)
10.1002/PATH.2182
Neuropilins in physiological and pathological angiogenesis.
C. Staton (2007)
10.1186/s12935-017-0390-1
Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell
Z. Su (2017)
10.1369/0022155413516347
How Vascular Endothelial Growth Factor-A (VEGF) Regulates Differentiation of Mesenchymal Stem Cells
A. D. Berendsen (2014)
10.1016/j.theriogenology.2017.01.028
Expression of the vascular endothelial growth factor system (VEGF) in the porcine oviduct during the estrous cycle.
Octavio López Albors (2017)
Modeling of interactions between vascular endothelial growth factor family members and their receptors KDR and Flt-1.
M. R. Rittler (2008)
10.1038/pr.2015.15
VEGF mRNA and Protein Concentrations in the Developing Human Eye
I. Ma (2015)
10.7717/peerj.3862
Effects of astragalus polysaccharide on the adhesion-related immune response of endothelial cells stimulated with CSFV in vitro
Z. Zhuge (2017)
Multigene Therapy by Ultrasound-mediated Plasmid Delivery: Temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 promotes sustained angiogenesis in chronically ischemic skeletal muscle
Alexandra H. Smith (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar